Gastric Cancer

Global Gastric Cancer Market to Reach US$8.4 Billion by 2030

The global market for Gastric Cancer estimated at US$3.3 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 16.9% over the analysis period 2024-2030. Adenocarcinoma, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$2.4 Billion by the end of the analysis period. Growth in the Lymphoma segment is estimated at 19.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$893.1 Million While China is Forecast to Grow at 21.9% CAGR

The Gastric Cancer market in the U.S. is estimated at US$893.1 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 21.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.8% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.4% CAGR.

Global Gastric Cancer Market – Key Trends & Drivers Summarized

Why Is Gastric Cancer Research Becoming More Critical for Global Health?

Gastric cancer remains one of the leading causes of cancer-related deaths worldwide, particularly in regions such as East Asia, Central and Eastern Europe, and parts of South America. The increasing recognition of its global health burden has spurred significant advancements in both early detection and treatment options. Gastric cancer is particularly challenging because it is often diagnosed at an advanced stage when treatment options are limited, and survival rates are low. This has led to a growing focus on early diagnostic tools and technologies, such as biomarker testing and advanced imaging techniques, to identify the disease at its earliest stages. Furthermore, there is an increasing emphasis on understanding the molecular mechanisms underlying gastric cancer development, which is crucial for identifying targeted therapies. In particular, research into the role of Helicobacter pylori infection, genetic mutations, and dietary factors has gained momentum, as these are identified as key risk factors for the disease. As a result, funding for gastric cancer research has risen, supported by both public and private health organizations, to advance treatment methods and improve patient outcomes. With the rise in global awareness of the disease and its complex nature, scientists are exploring new therapeutic approaches such as immunotherapy, precision medicine, and personalized cancer treatments, all of which are driving innovations in the fight against gastric cancer.

How Are Advances in Treatment Shaping the Gastric Cancer Landscape?

The treatment landscape for gastric cancer has evolved significantly over the past decade, with advancements in both surgical techniques and systemic therapies offering new hope for patients. In the past, surgery was the main treatment option for early-stage gastric cancer, but only a small percentage of patients were candidates for curative surgery at the time of diagnosis. However, with the advent of minimally invasive procedures, patients are now able to undergo less invasive surgeries, which reduce recovery times and improve post-operative outcomes. In addition to surgery, chemotherapy, radiation therapy, and targeted therapies have become essential components of the treatment regimen, particularly for advanced stages of gastric cancer. Targeted therapies, such as trastuzumab (Herceptin), have shown efficacy in treating HER2-positive gastric cancers, which make up a significant proportion of gastric cancer cases. More recently, immunotherapy has emerged as a promising treatment option, particularly for patients with advanced gastric cancer. Immune checkpoint inhibitors such as pembrolizumab (Keytruda) have demonstrated encouraging results, offering new avenues for patients who have exhausted other treatment options. Moreover, advancements in molecular profiling and genetic testing are allowing for more personalized treatment plans tailored to an individual’s specific tumor characteristics. As more therapies become available, there is an increased focus on combining these modalities for better outcomes, with clinical trials actively investigating the benefits of dual therapies, immunotherapy combined with chemotherapy, and other synergistic approaches to treating gastric cancer.

What Are the Key Factors Contributing to the Increasing Incidence of Gastric Cancer?

Several factors are contributing to the increasing global incidence of gastric cancer, with lifestyle and environmental influences playing a significant role in disease development. One of the major risk factors is infection with Helicobacter pylori, a bacterium that is known to cause chronic inflammation and increase the risk of gastric cancer. H. pylori infection is particularly prevalent in developing countries, but with better sanitation and medical treatments, its prevalence is decreasing in developed nations. However, other lifestyle-related factors, such as poor diet, smoking, and alcohol consumption, continue to be major contributors to the rising incidence of gastric cancer. Diets rich in salted, smoked, or pickled foods, which are common in many parts of the world, have been linked to an increased risk of gastric cancer. Additionally, obesity and lack of physical activity are emerging as significant risk factors, as they are known to increase inflammation and alter gut microbiota, both of which contribute to carcinogenesis. Genetic predisposition also plays a role, with certain inherited syndromes, such as hereditary diffuse gastric cancer (HDGC), putting individuals at higher risk. Additionally, age is a significant factor, with the risk of developing gastric cancer increasing significantly in individuals over 50. The rise in the incidence of gastric cancer can therefore be attributed to a combination of environmental, dietary, genetic, and lifestyle factors, along with the challenges of early detection and the ability to effectively treat the disease in its advanced stages.

What Are the Key Drivers Behind the Growth of the Gastric Cancer Treatment Market?

The growth of the gastric cancer treatment market is driven by several key factors, including advancements in medical research, increasing healthcare investments, and rising public awareness. As the incidence of gastric cancer continues to rise, particularly in countries with aging populations or high rates of The expansion of healthcare access, especially in developing countries, is also contributing to a larger patient population seeking treatment. Early diagnosis remains a significant challenge, but the development of more advanced screening and diagnostic tools has led to earlier detection in some regions, making treatment more effective and improving survival rates. The increasing focus on personalized medicine and precision oncology is another major driver, as treatments are becoming more tailored to an individual’s genetic and molecular profile, leading to more effective and targeted therapies. The integration of biomarkers and molecular diagnostics is enabling physicians to identify which treatments are most likely to benefit patients based on their tumor’s specific characteristics. Additionally, the growing interest in immunotherapy and its application to gastric cancer is another key factor propelling market growth. Immunotherapies, which harness the body’s immune system to fight cancer cells, are showing promise in treating patients with advanced or metastatic gastric cancer, and their development is accelerating the growth of the market. Furthermore, the pharmaceutical industry’s increasing focus on developing novel therapies and combination treatment regimens, as well as the rising number of clinical trials dedicated to gastric cancer, is expected to contribute to continued advancements and better patient outcomes, further driving the gastric cancer treatment market.

SCOPE OF STUDY:

The report analyzes the Gastric Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Disease Type (Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Disease Types); Treatment Type (Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy & Surgery); Drug Class (PD-1 / PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists, Other Drug Classes); Administration Route (Oral, Injectable); Distribution Channel (Specialty & Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Biohit Oyj
• Bristol-Myers Squibb Company
• Celltrion Healthcare Co., Ltd.
• Eli Lilly and Company
• Exalenz Bioscience Ltd.
• F. Hoffmann-La Roche Ltd.
• GeneMatrix Inc.
• GSK plc
• Imugene Limited
• Jiangsu Hengrui Medicine Co.
• Merck & Co., Inc.
• Novartis AG
• OBI Pharma, Inc.
• Pfizer Inc.
• Samsung Bioepis Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.